GlobeImmune Inc GBIM Stock Analysis
- PINK
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.00 unchanged at close Oct 14
Last close · Previous close $0.00
- Market cap
- At the Oct 14 close
- P/E ratio
- On last 12 months’ EPS
- Diluted EPS
- Last 12 months
- Dividend yield
- Last 12 months
Price chart
$0.00unchangedWed, Oct 14 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.00Oct 13
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Valuation
Financials
Dividends
About GlobeImmune Inc
GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and has completed Phase 2a clinical trial to treat non-small cell lung cancer, as well as in Phase 2a clinical study for the treatment of colorectal cancer. The companys product candidates also comprise GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer; GI-6301, which is in Phase 1 clinical trial for the treatment of chordoma and breast cancer; and GS-4774 that is in Phase 2 clinical trials to treat chronic hepatitis B virus. In addition, it is developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for chronic hepatitis D infection. The company has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune Inc. in May 2001. GlobeImmune Inc. was founded in 1995 and is headquartered in Louisville, Colorado.
- Sector
- Industry
- Headquarters
- Exchange
- PINK
- Asset type
- Common stock
- Price history since
GBIM news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
GBIM stock FAQ
What is GBIM stock’s price today?
GlobeImmune (GBIM) traded at $0.00 at the close on , unchanged from the previous close of $0.00.
What exchange does GBIM trade on?
GlobeImmune trades on the PINK under the ticker symbol GBIM. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.